# Amprius Technologies, Inc.: financial statements, quarterly

AMPX · NYSE · CIK 1899287 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ampx.md) · [Financials](/companies/ampx/financials.md) · [Filings](/companies/ampx/filings.md) · [Insiders](/companies/ampx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ampx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.8](/filings/0001899287-24-000088.md) | [3.7 d](/filings/0001899287-25-000012.md) | [2.3](/filings/0001899287-25-000040.md) | [3.3](/filings/0001628280-25-038983.md) | [7.9](/filings/0001628280-25-050308.md) | [10.0 d](/filings/0001899287-26-000015.md) | [11.3](/filings/0001899287-26-000045.md) | [15.1](/filings/0001899287-26-000059.md) | [21.4](/filings/0001628280-25-050308.md) | [24.1 d](/filings/0001899287-26-000015.md) | [28.5](/filings/0001899287-26-000045.md) | [34.0](/filings/0001899287-26-000059.md) |
| Cost of revenue | $m | [7.0](/filings/0001899287-24-000088.md) | [7.8 d](/filings/0001899287-25-000012.md) | [6.8](/filings/0001899287-25-000040.md) | [9.9](/filings/0001628280-25-038983.md) | [13.0](/filings/0001628280-25-050308.md) | [12.9 d](/filings/0001899287-26-000015.md) | [13.6](/filings/0001899287-26-000045.md) | [13.7](/filings/0001899287-26-000059.md) | [18.1](/filings/0001628280-25-050308.md) | [19.3 d](/filings/0001899287-26-000015.md) | [22.8](/filings/0001899287-26-000045.md) | [24.8](/filings/0001899287-26-000059.md) |
| Gross profit | $m | [(4.2)](/filings/0001899287-24-000088.md) | [(3.9) d](/filings/0001899287-25-000012.md) | [(4.4)](/filings/0001899287-25-000040.md) | [(6.5)](/filings/0001628280-25-038983.md) | [(5.1)](/filings/0001628280-25-050308.md) | [(2.3) d](/filings/0001899287-26-000015.md) | [(2.4)](/filings/0001899287-26-000045.md) | [1.3](/filings/0001899287-26-000059.md) | [3.3](/filings/0001628280-25-050308.md) | [6.0 d](/filings/0001899287-26-000015.md) | [5.7](/filings/0001899287-26-000045.md) | [9.3](/filings/0001899287-26-000059.md) |
| Research and development | $m | [0.8](/filings/0001899287-24-000088.md) | [1.3 d](/filings/0001899287-25-000012.md) | [1.6](/filings/0001899287-25-000040.md) | [1.7](/filings/0001628280-25-038983.md) | [1.8](/filings/0001628280-25-050308.md) | [2.3 d](/filings/0001899287-26-000015.md) | [2.0](/filings/0001899287-26-000045.md) | [2.2](/filings/0001899287-26-000059.md) | [2.5](/filings/0001628280-25-050308.md) | [2.8 d](/filings/0001899287-26-000015.md) | [3.8](/filings/0001899287-26-000045.md) | [4.1](/filings/0001899287-26-000059.md) |
| Selling, general and administrative | $m | [4.1](/filings/0001899287-24-000088.md) | [4.6 d](/filings/0001899287-25-000012.md) | [4.3](/filings/0001899287-25-000040.md) | [4.7](/filings/0001628280-25-038983.md) | [4.3](/filings/0001628280-25-050308.md) | [5.4 d](/filings/0001899287-26-000015.md) | [5.3](/filings/0001899287-26-000045.md) | [6.0](/filings/0001899287-26-000059.md) | [5.5](/filings/0001628280-25-050308.md) | [6.2 d](/filings/0001899287-26-000015.md) | [8.6](/filings/0001899287-26-000045.md) | [9.5](/filings/0001899287-26-000059.md) |
| Operating income | $m | [(9.1)](/filings/0001899287-24-000088.md) | [(9.7) d](/filings/0001899287-25-000012.md) | [(10.3)](/filings/0001899287-25-000040.md) | [(12.9)](/filings/0001628280-25-038983.md) | [(11.3)](/filings/0001628280-25-050308.md) | [(11.8) d](/filings/0001899287-26-000015.md) | [(9.7)](/filings/0001899287-26-000045.md) | [(6.8)](/filings/0001899287-26-000059.md) | [(4.7)](/filings/0001628280-25-050308.md) | [(25.5) d](/filings/0001899287-26-000015.md) | [(6.7)](/filings/0001899287-26-000045.md) | [(4.3)](/filings/0001899287-26-000059.md) |
| Income tax | $m | [0.0 d](/filings/0001899287-23-000117.md) | [0.0 d](/filings/0001899287-25-000012.md) | [0.0](/filings/0001899287-24-000048.md) | [0.0 d](/filings/0001899287-24-000065.md) | [0.0 d](/filings/0001899287-24-000088.md) | [0.0 d](/filings/0001899287-26-000015.md) | [0.0](/filings/0001899287-25-000040.md) | [0.0 d](/filings/0001628280-25-038983.md) | [0.0 d](/filings/0001628280-25-050308.md) | [0.0 d](/filings/0001899287-26-000015.md) | [0.0](/filings/0001899287-26-000045.md) | [0.0 d](/filings/0001899287-26-000059.md) |
| Net income | $m | [(8.5)](/filings/0001899287-24-000088.md) | [(9.7) d](/filings/0001899287-25-000012.md) | [(9.9)](/filings/0001628280-25-050308.md) | [(12.5)](/filings/0001628280-25-050308.md) | [(10.9)](/filings/0001628280-25-050308.md) | [(11.4) d](/filings/0001899287-26-000015.md) | [(9.4)](/filings/0001899287-26-000059.md) | [(6.4)](/filings/0001899287-26-000059.md) | [(3.9)](/filings/0001628280-25-050308.md) | [(24.4) d](/filings/0001899287-26-000015.md) | [(5.0)](/filings/0001899287-26-000059.md) | [(3.2)](/filings/0001899287-26-000059.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001899287-24-000088.md) | not reported | [(0.11)](/filings/0001899287-25-000040.md) | [(0.13)](/filings/0001628280-25-038983.md) | [(0.10)](/filings/0001628280-25-050308.md) | not reported | [(0.08)](/filings/0001899287-26-000045.md) | [(0.05)](/filings/0001899287-26-000059.md) | [(0.03)](/filings/0001628280-25-050308.md) | not reported | [(0.04)](/filings/0001899287-26-000045.md) | [(0.04)](/filings/0001899287-26-000059.md) |
| Basic EPS | $ per share | [(0.10)](/filings/0001899287-24-000088.md) | not reported | [(0.11)](/filings/0001899287-25-000040.md) | [(0.13)](/filings/0001628280-25-038983.md) | [(0.10)](/filings/0001628280-25-050308.md) | not reported | [(0.08)](/filings/0001899287-26-000045.md) | [(0.05)](/filings/0001899287-26-000059.md) | [(0.03)](/filings/0001628280-25-050308.md) | not reported | [(0.04)](/filings/0001899287-26-000045.md) | [(0.04)](/filings/0001899287-26-000059.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [53.4](/filings/0001899287-24-000088.md) | [45.8](/filings/0001899287-25-000012.md) | [39.0](/filings/0001899287-25-000040.md) | [46.4](/filings/0001628280-25-038983.md) | [35.0](/filings/0001628280-25-050308.md) | [55.2](/filings/0001899287-26-000015.md) | [48.4](/filings/0001899287-26-000045.md) | [54.2](/filings/0001899287-26-000059.md) | [73.2](/filings/0001628280-25-050308.md) | [90.5](/filings/0001899287-26-000059.md) | [62.4](/filings/0001899287-26-000045.md) | [74.5](/filings/0001899287-26-000059.md) |
| Current assets | $m | [61.4](/filings/0001899287-23-000117.md) | [50.5](/filings/0001899287-25-000012.md) | [45.6](/filings/0001899287-24-000048.md) | [53.0](/filings/0001899287-24-000065.md) | [44.9](/filings/0001899287-24-000088.md) | [68.8](/filings/0001899287-26-000015.md) | [66.1](/filings/0001899287-25-000040.md) | [71.9](/filings/0001628280-25-038983.md) | [107](/filings/0001628280-25-050308.md) | [126](/filings/0001899287-26-000059.md) | [114](/filings/0001899287-26-000045.md) | [132](/filings/0001899287-26-000059.md) |
| Total assets | $m | [86.6](/filings/0001899287-23-000117.md) | [108](/filings/0001899287-25-000012.md) | [105](/filings/0001899287-24-000048.md) | [113](/filings/0001899287-24-000065.md) | [104](/filings/0001899287-24-000088.md) | [121](/filings/0001899287-26-000015.md) | [118](/filings/0001899287-25-000040.md) | [123](/filings/0001628280-25-038983.md) | [156](/filings/0001628280-25-050308.md) | [157](/filings/0001899287-26-000059.md) | [131](/filings/0001899287-26-000045.md) | [149](/filings/0001899287-26-000059.md) |
| Current liabilities | $m | [13.9](/filings/0001899287-23-000117.md) | [13.5](/filings/0001899287-25-000012.md) | [9.8](/filings/0001899287-24-000048.md) | [12.8](/filings/0001899287-24-000065.md) | [13.0](/filings/0001899287-24-000088.md) | [17.2](/filings/0001899287-26-000015.md) | [14.0](/filings/0001899287-25-000040.md) | [12.1](/filings/0001628280-25-038983.md) | [16.1](/filings/0001628280-25-050308.md) | [17.9](/filings/0001899287-26-000059.md) | [16.0](/filings/0001899287-26-000045.md) | [18.4](/filings/0001899287-26-000059.md) |
| Total liabilities | $m | [20.9](/filings/0001899287-23-000117.md) | [47.9](/filings/0001899287-25-000012.md) | [44.8](/filings/0001899287-24-000048.md) | [47.6](/filings/0001899287-24-000065.md) | [48.2](/filings/0001899287-24-000088.md) | [51.7](/filings/0001899287-26-000015.md) | [48.1](/filings/0001899287-25-000040.md) | [46.4](/filings/0001628280-25-038983.md) | [53.3](/filings/0001628280-25-050308.md) | [53.1](/filings/0001899287-26-000059.md) | [21.4](/filings/0001899287-26-000045.md) | [23.5](/filings/0001899287-26-000059.md) |
| Shareholders' equity | $m | [65.8](/filings/0001899287-24-000088.md) | [59.8](/filings/0001899287-26-000015.md) | [59.9](/filings/0001628280-25-050308.md) | [65.1](/filings/0001628280-25-050308.md) | [56.0](/filings/0001628280-25-050308.md) | [69.5](/filings/0001899287-26-000059.md) | [70.4](/filings/0001899287-26-000059.md) | [76.7](/filings/0001899287-26-000059.md) | [103](/filings/0001628280-25-050308.md) | [104](/filings/0001899287-26-000059.md) | [109](/filings/0001899287-26-000059.md) | [126](/filings/0001899287-26-000059.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.7) d](/filings/0001899287-24-000088.md) | [(4.8) d](/filings/0001899287-25-000012.md) | [(9.8)](/filings/0001899287-25-000040.md) | [(8.0) d](/filings/0001628280-25-038983.md) | [(9.5) d](/filings/0001628280-25-050308.md) | [(6.1) d](/filings/0001899287-26-000015.md) | [(14.1)](/filings/0001899287-26-000045.md) | [(4.3) d](/filings/0001899287-26-000059.md) | [(9.2) d](/filings/0001628280-25-050308.md) | [(3.5) d](/filings/0001899287-26-000015.md) | [(37.3)](/filings/0001899287-26-000045.md) | [(2.9) d](/filings/0001899287-26-000059.md) |
| Capital expenditure | $m | [8.9 d](/filings/0001899287-24-000088.md) | [5.8 d](/filings/0001899287-25-000012.md) | [3.9](/filings/0001899287-25-000040.md) | [1.6 d](/filings/0001628280-25-038983.md) | [1.3 d](/filings/0001628280-25-050308.md) | [(3.6) d](/filings/0001899287-26-000015.md) | [0.9](/filings/0001899287-26-000045.md) | [0.7 d](/filings/0001899287-26-000059.md) | [0.4 d](/filings/0001628280-25-050308.md) | [2.4 d](/filings/0001899287-26-000015.md) | [1.0](/filings/0001899287-26-000045.md) | [1.8 d](/filings/0001899287-26-000059.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [69.0](/filings/0001899287-23-000117.md) | [84.6](/filings/0001899287-24-000048.md) | [85.2](/filings/0001899287-24-000065.md) | [86.4](/filings/0001899287-24-000088.md) | [90.0](/filings/0001899287-25-000040.md) | [97.0](/filings/0001628280-25-038983.md) | [110](/filings/0001628280-25-050308.md) | [118](/filings/0001899287-26-000045.md) | [122](/filings/0001899287-26-000059.md) | [127](/filings/0001628280-25-050308.md) | [137](/filings/0001899287-26-000045.md) | [143](/filings/0001899287-26-000059.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 146,080,618 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001899287-26-000059.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.